Results 31 to 40 of about 14,484 (178)

Experience and perspectives of distance learning of pharmacists-interns in the system of continuous education

Фармацевтичний журнал, 2019
Modernization of the educational process at the postgraduate stage using modern computer technologies is extremely urgent. The purpose of the study was to analyze the experience of distance learning of pharmacists-interns at the department of ...
Ya. O. Grynkiv, O. М. Zaliska, O. E. Sichkoriz   +2 more
doaj   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Is it time for China to prioritize pan-genotypic regimens for treating patients with hepatitis C?

Cost Effectiveness and Resource Allocation
Introduction The treatment of hepatitis C has entered the pan-genotypic era, but the effectiveness is not good for the genotype 3b patients who have a large proportion in China.
Yusi Tu, Xiangyan Tang, Dachuang Zhou, Hanqiao Shao, Leyi Liang, Wenxi Tang   +5 more
doaj   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Adverse events in bedaquiline‐ and pretomanid‐based regimens for drug‐resistant tuberculosis from trial, implementation and pharmacovigilance studies

British Journal of Clinical Pharmacology, EarlyView.
Abstract The availability of safety data, particularly concerning adverse events (AEs) associated with the new shorter regimen for drug‐resistant tuberculosis (TB) containing a bedaquiline–pretomanid‐based regimen, is still limited. This systematic review aims to provide a comprehensive and updated analysis of AEs related to this new regimen by ...
Nisa Maria, Annisa Lazuardi Larasati, Indri Yuliani Hamdani, Jin‐Gun Cho, Jan‐Willem C. Alffenaar   +4 more
wiley   +1 more source

Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis

Cardiovascular Diabetology, 2022
Background We conducted a systematic review and meta-analysis of the cardiovascular, kidney, and safety outcomes of sodium-glucose cotransporter 2 inhibitors (SGLT2i) among patients with diabetic kidney disease (DKD).
Arnaud D. Kaze, Min Zhuo, Seoyoung C. Kim, Elisabetta Patorno, Julie M. Paik   +4 more
doaj   +1 more source

Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis

Frontiers in Public Health, 2022
Background and ObjectiveUnresectable hepatocellular carcinoma (uHCC) is the main histological subtype of liver cancer and causes a great disease burden in China.
Mingye Zhao, Mingye Zhao, Xingming Pan, Xingming Pan, Yue Yin, Yue Yin, Hongfei Hu, Hongfei Hu, Jifu Wei, Zhaoshi Bai, Wenxi Tang, Wenxi Tang   +11 more
doaj   +1 more source

Precision medicine in paediatrics: Progress and priorities

British Journal of Clinical Pharmacology, EarlyView.
Precision medicine is revolutionizing personalized healthcare, advancing both diagnostics and therapeutics at an unprecedented pace. Reviewing the paediatric applications of pharmacometrics, pharmacogenomics and advanced therapy medicinal products highlights not only the relevance of these exciting innovations to frontline care but also the significant
Nicola Husain, Claire Booth, Joseph F. Standing, Charlotte I. S. Barker   +3 more
wiley   +1 more source

Exploring individualized crovalimab dosing in PNH through in silico modelling: Potential for improved convenience and cost efficiency

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired haematopoietic stem cell disorder. Crovalimab, a complement C5‐inhibitor, is approved for PNH and can be self‐administered subcutaneously every 4 weeks, offering a more convenient route than intravenous C5‐inhibitors.
Mendy ter Avest, Simon E. Koele, Nicole C. A. J. van de Kar, Saskia M. C. Langemeijer, Rob ter Heine   +4 more
wiley   +1 more source

Systematic Evaluation of Data and Trial Fitness for Oncology Trial Emulation: Empirical Findings from the CARE Initiative

Clinical Pharmacology &Therapeutics, EarlyView.
The Coalition to Advance Real‐World Evidence through Randomized Controlled Trial Emulation (CARE) Initiative seeks to advance understanding of when real‐world data (RWD) can generate valid treatment effectiveness estimates by emulating completed oncology randomized controlled trials (RCTs).
Natalie Levy, Paige Sheridan, Ulka Campbell, David Lenis, Inish O'Doherty, Adina Estrin, Nileesa Gautam, Monica Iyer, Sarah McDonald, Andrew Belli, Gillis Carrigan, K. Arnold Chan, James Chen, Victoria Chia, Neil Dhopeshwarkar, Joy Eckert, Laura Fernandes, Joel Greshock, Rachele Hendricks‐Sturrup, Jenny Huang, XiaoLong Jiao, Sajan Khosla, Orsolya Lunacsek, Lynn McRoy, Yanina Natanzon, Osayi Ovbiosa, Nelson Pace, Simone Pinheiro, Megan Rees, Jennifer Rider, Mothaffar Fahed Rimawi, Travis Robinson, Carla Rodriguez‐Watson, Chithra Sangli, Khaled Sarsour, Sebastian Schneeweiss, Mark Shapiro, Mark Stewart, Aliki Taylor, C. K. Wang, Shirley Wang, Yiduo Zhang, Ann Madsen   +42 more
wiley   +1 more source